ClinicalTrials.gg
CompletedNCT04481789Updated Jul 15, 2026Results posted

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

A Phase 1 interventional study of MT-1186 and Rosuvastatin in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Oct 2018, registered Jul 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
20 Years to 45 Years
Sex
Male
01

Study summary

  • Cohort 1: To evaluate the drug interactions, safety, and tolerability of oral edaravone when coadministered with rosuvastatin, sildenafil or furosemide in healthy adult males
  • Cohort 2: To evaluate the pharmacokinetics, safety, and tolerability of oral edaravone in healthy Japanese and Caucasian adult males
02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male volunteers
  • Cohort 1: Japanese, Cohort 2: Japanese or Caucasian
  • Subjects aged between 20 and 45 years at the time of
  • Subjects who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  • Subjects with a current or previous history of cardiac, hepatic, renal, gastrointestinal, respiratory, psychiatric/nervous, hematopoietic, or endocrine diseases, and those whom the investigator (or subinvestigator) deems unsuitable for the study
  • (BMI) of \<18.0 or >30.0, or body weight of \<50 kg (BMI formula: body weight [kg]/height [m]2, rounded to one decimal place)
  • Subjects who have undergone any surgery known to affect the gastrointestinal absorption of drugs
  • Subjects who do not agree to use an effective method of from initiation of study drug administration to 14 days after completion (discontinuation) of study drug administration
  • Subjects who have previously received edaravone
  • Subjects who have participated in another clinical study and received a study drug within 12 weeks before providing
  • Use of any drug(s) other than the study drug or as-needed use of acetylsalicylic acid within 7 days before the initiation of study drug or victim drug administration
  • Use of any alcohol, xanthine, or caffeine-containing product(s) within 24 hours before screening and Day -1 visiting
  • Use of any supplement(s) within 7 days before the initiation of study drug or victim drug administration
  • Use of grapefruit, grapefruit juice, or any processed food(s) containing these substances during the following periods (Cohort 1: within 7 days before the initiation of victim drug administration, Cohort 2: within 24 hours before each Day -1 visiting)
  • Use of any tobacco or nicotine-containing product(s) (Cohort 1: within 12 weeks before the initiation of victim drug administration during the following periods, Cohort 2: within 24 hours before each Day -1 visiting)
  • Use of any health food(s) containing St John's Wort (Hypericum perforatum) within 2 weeks before the initiation of victim drug administration (only in Cohort 1)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Rosuvastatin, Sildenafil, and MT-1186

    Group 1 of Cohort 1: A single-sequence study in which healthy male subjects receive a single dose of rosuvastatin on Day 1 followed by a single dose of sildenafil on Day 4. MT-1186 will be administered from Day 6 to 13 with co-administration of rosuvastatin and sildenafil on Day 9 and 12, respectively.

    Drug: MT-1186 · Drug: Rosuvastatin · Drug: Sildenafil

  • Experimental
    Furosemide and MT-1186

    Group 2 of Cohort 1: A single-sequence study in which healthy male subjects receive a single dose of furosemide on Day 1. MT-1186 will be administered from Day 3 to 7 with co-administration of furosemide on Day 6.

    Drug: MT-1186 · Drug: Furosemide

  • Experimental
    MT-1186

    Cohort 2: A three-way crossover study in which Japanese healthy male subjects receive a single dose of MT-1186 under several dosing condition on Day 1, 4, and 7 according to their treatment sequence with 3-day wash out between doses. Caucasian healthy male subjects receive a single dose of MT-1186 at the same period with Japanese subjects under the corresponding condition on Day 1, 4, or 7 according to their treatment schedule.

    Drug: MT-1186

Interventions

  • Suspension

    Also known as: Edaravone

  • DrugRosuvastatin

    Tablets

    Also known as: Crestor

  • Tablets

    Also known as: Viagra

  • Tablets

    Also known as: Lasix

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide.

    Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose

  2. Maximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide.

    Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose

  3. Tmax of Rosuvastatin, Sildenafil and Furosemide.

    Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose

  4. T1/2 of Rosuvastatin, Sildenafil and Furosemide.

    Time frame: Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose

  5. AUC0-inf of Unchanged Edaravone.

    Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  6. Cmax of Unchanged Edaravone.

    Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  7. Tmax of Unchanged Edaravone.

    Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  8. T1/2 of Unchanged Edaravone.

    Time frame: Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  9. AUC0-inf of Sulfate Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  10. Cmax of Sulfate Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  11. Tmax of Sulfate Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  12. T1/2 of Sulfate Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  13. AUC0-inf of Glucuronide Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  14. Cmax of Glucuronide Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  15. Tmax of Glucuronide Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  16. T1/2 of Glucuronide Conjugate.

    Time frame: Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.

  17. AUC0-inf of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  18. Cmax of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  19. Tmax of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  20. T1/2 of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  21. AUCinf of Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  22. Cmax of Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  23. Tmax of Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  24. T1/2 of Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  25. T1/2 of Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  26. Number of Participants With Adverse Events and Adverse Drug Reactions

    Time frame: Day 1 to 20 in group 1 of cohort 1, Day 1 to 14 in group 2 of cohort 1, Day 1 to 14 of cohort 2

Secondary outcomes

  1. AUCinf of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  2. Cmax of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  3. Tmax of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

  4. T1/2 of Unchanged Edaravone.

    Time frame: Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose

07

Results

Posted Aug 2, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneRosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Edaravone Group 3 of Cohort 2Edaravone Group 4 of Cohort 2Edaravone Group 5 of Cohort 2Caucasian Group of Cohort 2
Started32343333
Completed31343333
Not completed100000
Withdrew: Withdrawal by subject100000
Period 2
Participant flow — Period 2
MilestoneRosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Edaravone Group 3 of Cohort 2Edaravone Group 4 of Cohort 2Edaravone Group 5 of Cohort 2Caucasian Group of Cohort 2
Started31343333
Completed31343333
Not completed000000
Period 3
Participant flow — Period 3
MilestoneRosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Edaravone Group 3 of Cohort 2Edaravone Group 4 of Cohort 2Edaravone Group 5 of Cohort 2Caucasian Group of Cohort 2
Started3103333
Completed3103333
Not completed000000

Outcome measures

PrimaryArea Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide.
Time frame:
Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Reported as:
Mean · ng*h/mL
Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide.
ng*h/mLRosuvastatin Alone: Group 1 of Cohort 1Rosubastatin + Edaravone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Sildenafil + Edaravone: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Furosemide + Edaravone: Group 2 of Cohort 1
Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Rosuvastatin, Sildenafil and Furosemide.161 ± 66.8165 ± 60.2532 ± 236482 ± 1953861 ± 10313906 ± 736.2
Statistical analysis
  • Rosuvastatin Alone: Group 1 of Cohort 1 vs Rosubastatin + Edaravone: Group 1 of Cohort 1 · Ls mean ratio: 1.02 · 90% CI 0.97 to 1.08
  • Sildenafil Alone: Group 1 of Cohort 1 vs Sildenafil + Edaravone: Group 1 of Cohort 1 · Ls mean ratio: 0.93 · 90% CI 0.88 to 0.99
  • Furosemide Alone: Group 2 of Cohort 1 vs Furosemide + Edaravone: Group 2 of Cohort 1 · Ls mean ratio: 1.03 · 90% CI 0.98 to 1.09
PrimaryMaximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide.
Time frame:
Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Reported as:
Mean · ng/mL
Maximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide.
ng/mLRosuvastatin Alone: Group 1 of Cohort 1Rosubastatin + Edaravone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Sildenafil + Edaravone: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Furosemide + Edaravone: Group 2 of Cohort 1
Maximum Plasma Concentration (Cmax) of Rosuvastatin, Sildenafil and Furosemide.11.3 ± 5.011.3 ± 5.0232 ± 135201 ± 97.91676 ± 777.71701 ± 506.5
Statistical analysis
  • Rosuvastatin Alone: Group 1 of Cohort 1 vs Rosubastatin + Edaravone: Group 1 of Cohort 1 · Ls mean ratio: 0.98 · 90% CI 0.91 to 1.06
  • Sildenafil Alone: Group 1 of Cohort 1 vs Sildenafil + Edaravone: Group 1 of Cohort 1 · Ls mean ratio: 0.94 · 90% CI 0.80 to 1.10
  • Furosemide Alone: Group 2 of Cohort 1 vs Furosemide + Edaravone: Group 2 of Cohort 1 · Ls mean ratio: 1.08 · 90% CI 0.96 to 1.23
PrimaryTmax of Rosuvastatin, Sildenafil and Furosemide.
Time frame:
Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Reported as:
Mean · h
Tmax of Rosuvastatin, Sildenafil and Furosemide.
hRosuvastatin Alone: Group 1 of Cohort 1Rosubastatin + Edaravone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Sildenafil + Edaravone: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Furosemide + Edaravone: Group 2 of Cohort 1
Tmax of Rosuvastatin, Sildenafil and Furosemide.4.6 ± 1.55.1 ± 1.40.8 ± 0.40.9 ± 0.51.7 ± 1.11.8 ± 1.1
PrimaryT1/2 of Rosuvastatin, Sildenafil and Furosemide.
Time frame:
Before rosuvastatin dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before sildenafil dosing and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose, Before furosemide dosing and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 hrs post-dose
Reported as:
Mean · h
T1/2 of Rosuvastatin, Sildenafil and Furosemide.
hRosuvastatin Alone: Group 1 of Cohort 1Rosubastatin + Edaravone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Sildenafil + Edaravone: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Furosemide + Edaravone: Group 2 of Cohort 1
T1/2 of Rosuvastatin, Sildenafil and Furosemide.14.4 ± 4.012.1 ± 2.22.8 ± 1.13.5 ± 1.46.9 ± 3.55.8 ± 3.8
PrimaryAUC0-inf of Unchanged Edaravone.
Time frame:
Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng*h/mL
AUC0-inf of Unchanged Edaravone.
ng*h/mLRosuvastatin, Sildenafil, and Edaravone: Group 1 of Cohort 1Furosemide and Edaravone: Group 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)—2535 ± 919
Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide)2616 ± 7302746 ± 1015
Day 9: Group 1 (Edaravone + Rosuvastatin), Group 2 Not Applicable2591 ± 671—
Day 12: Group 1 (Edaravone + Sildenafil), Group 2 Not Applicable2656 ± 712—
PrimaryCmax of Unchanged Edaravone.
Time frame:
Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng/mL
Cmax of Unchanged Edaravone.
ng/mLGroup 1 of Cohort 1Furosemide and Edaravone: Group 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)—2180 ± 1035
Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide)2724 ± 15332074 ± 1051
Day 9: Group 1 (Edaravone + Rosuvastatin)2302 ± 943—
Day 12: Group 1 (Edaravone + Sildenafil)2455 ± 1111—
PrimaryTmax of Unchanged Edaravone.
Time frame:
Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
Tmax of Unchanged Edaravone.
hGroup 1 of Cohort 1Furosemide and Edaravone: Group 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)—0.34 ± 0.19
Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide)0.30 ± 0.100.34 ± 0.17
Day 9: Group 1 (Edaravone + Rosuvastatin)0.34 ± 0.13—
Day 12: Group 1 (Edaravone + Sildenafil)0.32 ± 0.17—
PrimaryT1/2 of Unchanged Edaravone.
Time frame:
Group 1 (Day 6, 9 and 12) and Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
T1/2 of Unchanged Edaravone.
hGroup 1 of Cohort 1Furosemide and Edaravone: Group 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)—4.67 ± 0.92
Day 6: Group 1 (Edaravpne alone), Group 2 (Edaravone + Furosemide)5.23 ± 1.115.52 ± 0.60
Day 9: Group 1 (Edaravone + Rosuvastatin)6.60 ± 1.18—
Day 12: Group 1 (Edaravone + Sildenafil)6.69 ± 1.31—
PrimaryAUC0-inf of Sulfate Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng*h/mL
AUC0-inf of Sulfate Conjugate.
ng*h/mLGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)26576 ± 6820
Day 6: Group 2 (Edaravone + Furosemide)30588 ± 7064
PrimaryCmax of Sulfate Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng/mL
Cmax of Sulfate Conjugate.
ng/mLGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)8115 ± 1775
Day 6: Group 2 (Edaravone + Furosemide)8702 ± 2147
PrimaryTmax of Sulfate Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
Tmax of Sulfate Conjugate.
hGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)0.76 ± 0.28
Day 6: Group 2 (Edaravone + Furosemide)0.81 ± 0.30
PrimaryT1/2 of Sulfate Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
T1/2 of Sulfate Conjugate.
hGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)3.89 ± 0.25
Day 6: Group 2 (Edaravone + Furosemide)4.20 ± 0.33
PrimaryAUC0-inf of Glucuronide Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng*h/mL
AUC0-inf of Glucuronide Conjugate.
ng*h/mLGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)4817 ± 1282
Day 6: Group 2 (Edaravone + Furosemide)4953 ± 1285
PrimaryCmax of Glucuronide Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · ng/mL
Cmax of Glucuronide Conjugate.
ng/mLGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)2318 ± 649
Day 6: Group 2 (Edaravone + Furosemide)2304 ± 694
PrimaryTmax of Glucuronide Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
Tmax of Glucuronide Conjugate.
hGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)0.61 ± 0.26
Day 6: Group 2 (Edaravone + Furosemide)0.57 ± 0.18
PrimaryT1/2 of Glucuronide Conjugate.
Time frame:
Group 2 (Day 3 and 6): Pre-dose, 0.083, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post-dose.
Reported as:
Mean · h
T1/2 of Glucuronide Conjugate.
hGroup 2 of Cohort 1
Day 3: Group 2 (Edaravone alone)3.65 ± 0.28
Day 6: Group 2 (Edaravone + Furosemide)3.97 ± 0.31
PrimaryAUC0-inf of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng*h/mL
AUC0-inf of Unchanged Edaravone.
ng*h/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
AUC0-inf of Unchanged Edaravone.1647 ± 4331475 ± 6581247 ± 425
Statistical analysis
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 1 Hour After a High-fat Meal · Ls mean ratio: 0.842 · 90% CI 0.697 to 1.017
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 4 Hours After a High-fat Meal · Ls mean ratio: 0.737 · 90% CI 0.610 to 0.891
PrimaryCmax of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng/mL
Cmax of Unchanged Edaravone.
ng/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Cmax of Unchanged Edaravone.1810 ± 849.81502 ± 12721012 ± 603.3
Statistical analysis
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 1 Hour After a High-fat Meal · Ls mean ratio: 0.657 · 90% CI 0.379 to 1.137
  • Edaravone Single Dose Under Fasting Condition vs Edaravone Single Dose 4 Hours After a High-fat Meal · Ls mean ratio: 0.522 · 90% CI 0.301 to 0.903
PrimaryTmax of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Median · h
Tmax of Unchanged Edaravone.
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Tmax of Unchanged Edaravone.0.25 (0.25 to 1.00)0.50 (0.25 to 1.50)0.25 (0.25 to 1.00)
PrimaryT1/2 of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
T1/2 of Unchanged Edaravone.
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
T1/2 of Unchanged Edaravone.9.33 ± 4.879.65 ± 5.417.66 ± 4.12
PrimaryAUCinf of Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng*h/mL
AUCinf of Sulfate Conjugate and Glucuronide Conjugate.
ng*h/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Sulfate conjugate24484 ± 586122689 ± 633423022 ± 5094
Glucuronide conjugate4178 ± 8734099 ± 6373557 ± 879
PrimaryCmax of Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng/mL
Cmax of Sulfate Conjugate and Glucuronide Conjugate.
ng/mLEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Sulfate conjugate8394 ± 16097802 ± 15568152 ± 1731
Glucuronide conjugate2391 ± 5082176 ± 4751924 ± 380
PrimaryTmax of Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
Tmax of Sulfate Conjugate and Glucuronide Conjugate.
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Sulfate conjugate0.67 ± 0.250.91 ± 0.390.72 ± 0.26
Glucuronide conjugate0.53 ± 0.200.76 ± 0.350.72 ± 0.26
PrimaryT1/2 of Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
T1/2 of Sulfate Conjugate and Glucuronide Conjugate.
hEdaravone Single Dose Under Fasting ConditionEdaravone Single Dose 1 Hour After a High-fat MealEdaravone Single Dose 4 Hours After a High-fat Meal
Sulfate conjugate10.50 ± 7.677.53 ± 3.557.55 ± 2.47
Glucuronide conjugate4.26 ± 0.383.89 ± 0.793.88 ± 0.55
PrimaryT1/2 of Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
T1/2 of Glucuronide Conjugate.
hJapaneseWhite
T1/2 of Glucuronide Conjugate.4.26 ± 0.384.35 ± 0.25
PrimaryNumber of Participants With Adverse Events and Adverse Drug Reactions
Time frame:
Day 1 to 20 in group 1 of cohort 1, Day 1 to 14 in group 2 of cohort 1, Day 1 to 14 of cohort 2
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Adverse Drug Reactions
ParticipantsRosuvastatin Alone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Edaravone Alone: Group 1 of Cohort 1Edaravone + Rosuvastatin: Group 1 of Cohort 1Edaravone + Sildenafil: Group 1 of Cohort 1Combined: After Day 6: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Edaravone Alone: Group 2 of Cohort 1Edaravone + Furosemide: Group 2 of Cohort 1Combined : After Day 3: Group 2 of Cohort 1Edaravone Single Dose Under Fasting Condition: Japanese ConmibedEdaravone Single Dose 1 Hour After a High-fat Meal: Japanese ConmibedEdaravone Single Dose 4 Hours After a High-fat Meal: Japanese ConmibedEdaravone Single Dose Under Fasting Condition: White Conbined
Number of Participants with Adverse events02063810770200
Number of Participants with adverse drug reactions00050500000100
SecondaryAUCinf of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng*h/mL
AUCinf of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
ng*h/mLJapaneseWhite
Unchanged edaravone1647 ± 4331423 ± 391
Sulfate conjugate24484 ± 586120098 ± 1592
Glucuronide conjugate4178 ± 8733795 ± 571
SecondaryCmax of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · ng/mL
Cmax of Unchanged Edaravone, Sulfate Conjugate and Glucuronide Conjugate.
ng/mLJapaneseWhite
Unchanged edaravone1810 ± 8501484 ± 920
Sulfate conjugate8394 ± 16096530 ± 787
Glucuronide conjugate2391 ± 5082136 ± 403
SecondaryTmax of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
Tmax of Unchanged Edaravone.
hJapaneseWhite
Unchanged edaravone0.4 ± 0.30.4 ± 0.2
Sulfate conjugate0.67 ± 0.250.67 ± 0.25
Glucuronide conjugate0.53 ± 0.200.61 ± 0.22
SecondaryT1/2 of Unchanged Edaravone.
Time frame:
Before dosing, and 0.083, 0.25, 0.5 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 36 and 48 hours post-dose
Reported as:
Mean · h
T1/2 of Unchanged Edaravone.
hJapaneseWhite
Unchanged edaravone9.3 ± 4.916.2 ± 15.8
Sulfate conjugate10.5 ± 7.710.7 ± 6.5
Glucuronide conjugate4.3 ± 0.44.4 ± 0.3

Adverse events

Collected over Cohort 1 Group 1: Day 1 to Day 20. Cohort 1 Group 2 and Cohort 2: Day 1 to Day 14.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin Alone: Group 1 of Cohort 10/32 (0%)0/32 (0%)0/32 (0%)
Sildenafil Alone: Group 1 of Cohort 10/31 (0%)0/31 (0%)2/31 (6.5%)
Edaravone Alone: Group 1 of Cohort 10/31 (0%)0/31 (0%)0/31 (0%)
Edaravone + Rosuvastatin: Group 1 of Cohort 10/31 (0%)0/31 (0%)6/31 (19.4%)
Edaravone + Sildenafil: Group 1 of Cohort 10/31 (0%)0/31 (0%)3/31 (9.7%)
Combined: After Day 6: Group 1 of Cohort 10/31 (0%)0/31 (0%)8/31 (25.8%)
Furosemide Alone: Group 2 of Cohort 10/34 (0%)0/34 (0%)1/34 (2.9%)
Edaravone Alone: Group 2 of Cohort 10/34 (0%)0/34 (0%)0/34 (0%)
Edaravone + Furosemide: Group 2 of Cohort 10/34 (0%)0/34 (0%)7/34 (20.6%)
Combined : After Day 3: Group 2 of Cohort 10/34 (0%)0/34 (0%)7/34 (20.6%)
Edaravone Single Dose Under Fasting Condition: Japanese Conmibed0/9 (0%)0/9 (0%)0/9 (0%)
Edaravone Single Dose 1 Hour After a High-fat Meal: Japanese Conmibed0/9 (0%)0/9 (0%)2/9 (22.2%)
Edaravone Single Dose 4 Hours After a High-fat Meal: Japanese Conmibed0/9 (0%)0/9 (0%)0/9 (0%)
Edaravone Single Dose Under Fasting Condition: White Combined0/9 (0%)0/9 (0%)0/9 (0%)
Most frequent other events
Most frequent other events
EventRosuvastatin Alone: Group 1 of Cohort 1Sildenafil Alone: Group 1 of Cohort 1Edaravone Alone: Group 1 of Cohort 1Edaravone + Rosuvastatin: Group 1 of Cohort 1Edaravone + Sildenafil: Group 1 of Cohort 1Combined: After Day 6: Group 1 of Cohort 1Furosemide Alone: Group 2 of Cohort 1Edaravone Alone: Group 2 of Cohort 1Edaravone + Furosemide: Group 2 of Cohort 1Combined : After Day 3: Group 2 of Cohort 1Edaravone Single Dose Under Fasting Condition: Japanese ConmibedEdaravone Single Dose 1 Hour After a High-fat Meal: Japanese ConmibedEdaravone Single Dose 4 Hours After a High-fat Meal: Japanese ConmibedEdaravone Single Dose Under Fasting Condition: White Combined
Alanine aminotransferase increasedInvestigations0/320/310/311/312/313/310/340/340/340/340/92/90/90/9
AnaemiaBlood and lymphatic system disorders0/320/310/310/310/310/310/340/345/345/340/90/90/90/9
DiarrhoeaGastrointestinal disorders0/320/310/314/310/314/310/340/340/340/340/90/90/90/9
Aspartate aminotransferase increasedInvestigations0/320/310/311/310/311/310/340/340/340/340/91/90/90/9
Blood creatine phosphokinase increasedInvestigations0/320/310/310/310/310/310/340/340/340/340/91/90/90/9
Blood lactate dehydrogenase increasedInvestigations0/320/310/310/310/310/310/340/340/340/340/91/90/90/9
HeadacheNervous system disorders0/322/310/310/310/310/311/340/343/343/340/90/90/90/9
Abnormal sensation in eyeEye disorders0/320/310/310/311/311/310/340/340/340/340/90/90/90/9
PalpitationsCardiac disorders0/320/310/311/310/311/310/340/340/340/340/90/90/90/9
Nasal congestionRespiratory, thoracic and mediastinal disorders0/321/310/310/310/310/310/340/340/340/340/90/90/90/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Japanese Combined of Cohort 2Caucasian Group of Cohort 2Total
<=18 years00000
Between 18 and 65 years32349984
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Japanese Combined of Cohort 2Caucasian Group of Cohort 2Total
Female00000
Male32349984
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rosuvastatin, Sildenafil, and Edaravone Group 1 of Cohort 1Furosemide and Edaravone Group 2 of Cohort 1Japanese Combined of Cohort 2Caucasian Group of Cohort 2Total
American Indian or Alaska Native00000
Asian32349075
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00099
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Shimizu H, Nishimura Y, Shiide Y, Akimoto M, Matsuda H, Kato Y, Hirai M. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clin Ther. 2022 Dec;44(12):1552-1565. doi: 10.1016/j.clinthera.2022.10.001. Epub 2022 Nov 12. PubMed 36376130 ↗
  • Shimizu H, Nishimura Y, Shiide Y, Matsuda H, Akimoto M, Matsuda M, Nakamaru Y, Kato Y, Kondo K. Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1174-1187. doi: 10.1002/cpdd.925. Epub 2021 Mar 11. PubMed 33704925 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Dec 2018, 2 months.

Results were first posted in Aug 2024, 5 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 22, 2020
StartActual
Oct 17, 2018
Primary completionActual
Dec 20, 2018
CompletionActual
Jan 8, 2019
Results first posted
Aug 2, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04481789
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jul 22, 2020
Start date
Oct 17, 2018
Primary completion
Dec 20, 2018
Completion
Jan 8, 2019
Results posted
Aug 2, 2024
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion